Sign inCreate account

Report workspace tools

NCT07184918COMPLETEDanonymous

Clinical Study Evaluating the Effect of Continuing or Discontinuing Angiotensin-Converting Enzyme Inhibitor on Renal Function in Patients Undergoing Coronary Angiography

Sponsor

Source record

Tanta University

Phase

Source record

NA

Modality

AI-normalized

small molecule

Target

AI-normalized

Continuing Ramipril, Withholding Ramipril

Indication / condition

AI-normalized

Contrast-Induced Nephropathy

Intervention

Source record

Continuing Ramipril, Withholding Ramipril

Source & freshness

Source record

NCT ID

NCT07184918

Original source

ClinicalTrials.gov

Source last updated

Sep 22, 2025

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07184918

Title

Clinical Study Evaluating the Effect of Continuing or Discontinuing Angiotensin-Converting Enzyme Inhibitor on Renal Function in Patients Undergoing Coronary Angiography

Sponsor

Tanta University

Status

COMPLETED

Phase

NA

Condition raw

Contrast-Induced Nephropathy, Coronary Angiography, Acute Kidney Injury

Condition normalized

Contrast-Induced Nephropathy, Coronary Angiography, Acute Kidney Injury

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Continuing Ramipril, Withholding Ramipril

Target normalized

Continuing Ramipril, Withholding Ramipril

Interventions

Continuing Ramipril, Withholding Ramipril

Public preview

Source record

This clinical trial evaluates whether continuing or withholding ACE inhibitors (specifically Ramipril) before coronary angiography affects the risk of contrast-induced nephropathy (CIN). CIN is a known complication of iodinated contrast exposure, particularly in patients with chronic conditions such as hypertension or diabetes. The trial involves 44 adult patients randomized into two groups: one continuing Ramipril and the other withholding it 48 hours before and restarting 72 hours after the procedure. Renal biomarkers including serum creatinine, NGAL, and superoxide dismutase will be assessed to evaluate renal function.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Clinical Study Evaluating the Effect of Continuing or Discontinuing Angiotensin-Converting Enzyme Inhibitor on Renal Function in Patients Undergoing Coronary Angiography

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07184918

Status

COMPLETED

Phase

NA

Sponsor

Tanta University

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates whether continuing or withholding ACE inhibitors (specifically Ramipril) before coronary angiography affects the risk of contrast-induced nephropathy (CIN). CIN is a known complication of iodinated contrast exposure, particularly in patients with chronic conditions such as hypertension or diabetes. The trial involves 44 adult patients randomized into two groups: one continuing Ramipril and the other withholding it 48 hours before and restarting 72 hours after the procedure. Renal biomarkers including serum creatinine, NGAL, and superoxide dismutase will be assessed to evaluate renal function.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 22, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07184918

Indication

Contrast-Induced Nephropathy

Modality

small molecule

Target

Continuing Ramipril, Withholding Ramipril

Intervention

Continuing Ramipril, Withholding Ramipril

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.